Aurora Cannabis Archives - Green Market Report

Debra BorchardtDebra BorchardtDecember 23, 2019


Aurora Cannabis Inc. (NYSE: ACB) provided an update on its operations with the introduction of new product formats, recent industry recognitions, and updates to existing operations. It didn’t seem to have the intended effect as the stock dropped another 7% to lately trade at $2.06.

Aurora disappointed shareholders last month when the company reported that its consumer cannabis revenues fell 33% sequentially from the previous quarter. The decline in cannabis net revenues was attributed ordering that slowed considerably during the summer as distributors worked through inventories and as the industry was impacted by the slow pace of retail store licenses.

“We have focused our collective efforts to be ready for the successful launch of Cannabis 2.0 as Canada takes the next step in the legalization of newly allowed product forms. We are ready and have launched a diversified portfolio of new product formats and are excited for Canadians to have access to high-quality, safe alternative cannabis products such as edibles, vape pens and other derivatives,” said Terry Booth, CEO of Aurora. “We have prudently deployed capital and we believe that we’re ready with the appropriate combination of technology, scale and consumer insights to have the right products on store shelves in a timely fashion. This was not an easy task and I would like to thank the entire Aurora team for their collective efforts in getting 2.0 across the goal line in time for our provincial regulators.”

The company said it trying to reduce expenses, cut near term debt and bolster liquidity in an effort to position itself for long-term success. The previously announced deferral of construction and commissioning activities is expected to conserve approximately $200 million of cash in the near term. Aurora believes that its existing assets are sufficient to meet current demand at a low cost per gram. The company said it expects to have the flexibility to ramp up projects as global demand dictates.

In late November, the company also retired $227 million of the $230 million 5% unsecured convertible  debentures that were due in March 2020 with the issuance of shares and thereby preserving cash. Aurora continues to evaluate multiple sources of capital and currently has access to undrawn capacity under a C$360 million credit facility with a syndicate of banks, in addition to its $400 million at-the-market equity distribution program.

New Products

Aurora said it started shipping initial orders received to ten of Canada’s provincial regulators of Cannabis 2.0 products following December 17, 2019, however, the company cautioned that most Canadian consumers will likely not see these products on retail store shelves until early January 2020 due to varied retail operations across the country. Patients can now immediately access a variety of the new product formats.

Initially, the company said it is providing a variety of CBD and THC vape and edible products, such as gummies, chocolates, baked goods, and mints. These new cannabis products are being produced at Aurora Sky in Edmonton, Alberta, Aurora River in Bradford, Ontario and Aurora Vie in Pointe-Claire, Quebec. These centers have been outfitted to provide centralized production, packaging, logistics and distribution capabilities. The Company has prioritized its resources to prepare for a successful initial launch and has built inventories to support an ongoing replenishment strategy to help ensure consumers across Canada have access to a diverse portfolio of high-quality derivative products.

Debra BorchardtDebra BorchardtNovember 15, 2019


Aurora Cannabis Inc.  (NYSE: ACB) stock was selling off by over 8% in pre-market trading after the Canadian cannabis company reported its earnings following the market close on Thursday. Aurora delivered total revenue for its first fiscal quarter in Canadian dollars of $75.6 million which missed analyst estimates by $17 million. The first quarter GAAP EPS of C$0.01 did beat estimates by C$0.06.

The company said its consumer cannabis revenues were $30 million in the quarter, a 33% sequential drop and contributed 40% to total consolidated net revenue. The decline in cannabis net revenues was attributed ordering that slowed considerably during the summer as distributors worked through inventories and as the industry was impacted by the slow pace of retail store licensing.

“Over the past several years, Aurora has earned its place as a global leader in the cannabis industry. Despite short term distribution and regulatory headwinds in Canada that have temporarily impacted the industry, the long-term opportunity for Aurora in the global cannabis and cannabinoids market is immense,” said Terry Booth, CEO, Aurora Cannabis. “Aurora has and will continue to focus on everything in our control. Our success in doing this was demonstrated again this quarter by continued strong improvement in our core KPIs. We delivered solid operating results this quarter, exemplified by our industry-leading cash cost to produce which declined another 25% to $0.85 per gram this quarter, as well as by our industry-leading gross margins and market share.”

Scaling Back

Aurora said it decided to stop construction activity at its Aurora Nordic 2 facility in Denmark, which is expected to save approximately $80 million over the next 12 months. Aurora Nordic 1 is fully completed and has received a production license, and the company expects to receive a license to sell shortly. Aurora also decided to defer the majority of the final construction and commissioning activities at its Aurora Sun facility for the foreseeable future which is expected to conserve approximately $110 million of cash. The company said that as global demand develops, or as Aurora’s market share in the global cannabis market increases, it will reactivate these projects.

Medical Is Strong

The company’s medical cannabis net revenue increased 3% quarter-over-quarter to over $30 million. On the company’s earnings call, CFO Glen Ibbott said the increase was “driven by our continued success in growing our patient base, which currently stands at just over 91,000 clients. Our revenue was affected by a slight decrease in the average net selling price of medical cannabis of 6%, but more than offset by patient growth. The decline in selling price was the result of temporary pricing incentives designed to support the move of valuable long-term medical patients to Aurora, and away from LPs that we’re not servicing them well.”

Cost To Produce Drops

Aurora has always had a goal to be a low-cost producer and that mission seems to be fulfilled. Booth said, “I’m also proud to report that our high-tech cultivation facilities delivered on our promise to provide industry-leading indoor cash cost to produce below $1 a gram. And in fact, this quarter we came in well ahead of our expectations at $0.85 a gram.”

Looking Ahead

Aurora said that it knew this quarter would be tough and that it expected a growth plateau. Vapes and edible products will soon be available for sale and the company said that this will bring back sales.

Mr. Booth added, “In order to capitalize on this global market, we recognize the need to be nimble and proactive. To enhance our financial flexibility and position us to take maximum advantage of future growth opportunities, we have also taken decisive steps to immediately strengthen our balance sheet. Specifically, these steps include: (1) the announcement of a formal plan to settle our 5.0% convertible debentures due March 2020, (2) a reduction in our capital investments over the next several quarters by over $190 million to better match near-term capacity expansion with anticipated demand, while maintaining our long-term demand outlook, and (3) raising over US$124 million in gross equity proceeds since the start of fiscal 2020 through our at-the-market (“ATM”) financing program.”

“We view these as short-term headwinds and despite them, Aurora has continued to maintain our position as the leading producer and supplier of high quality medical and consumer cannabis products,” said Booth on the earnings call.

Debra BorchardtDebra BorchardtOctober 3, 2019


Just about every cannabis stock has suffered a drop in valuation in 2019. As a result, companies seem to feel they need to hold the investor’s hands by issuing statements of company health. The latest is Aurora Cannabis Inc.  (NYSE: ACB) who provided a corporate update that didn’t really give any ‘new’ news.

“Aurora takes its leadership position in the global cannabis industry seriously, and is committed to being open and transparent with all of our stakeholders,” said Terry Booth, CEO of Aurora. “The Aurora team is working to advance several major strategic initiatives in Canada, the United States and abroad aimed at further strengthening Aurora’s global position. We are laser-focused on delivering on our business plan and prudently managing our investors’ capital.”

The market though didn’t respond in the manner that was hoped for as the stock sold off another 7% and was lately trading at $4.12, which is lower than the 52-week high of $12.52. The update mostly reviewed the various grow facilities and construction status.

Update on Facilities in Construction:

As Aurora executes on its strategy of leading scalable, purpose-built cultivation, it continues to prudently manage capital allocation decisions driven by global forecasts for demand. Many of the Company’s significant construction projects are nearing completion of major milestones with significant capital investments concluded.

Aurora Sun and Aurora Nordic 2 Construction Update

Aurora continues to progress construction of its 1.6 million square foot facility, Aurora Sun, located in Medicine Hat, Alberta, and its 1 million square foot facility, Nordic Sky, strategically located in Odense, Denmark. The new purpose-built, “Sky Class” facilities Aurora are constructing will have full control over all anticipated environmental and harvest conditions, resulting in the production of consistently high yielding, high-quality cannabis at low-cost.

Mr. Booth added, “Aurora Sun in Medicine Hat and Aurora Nordic in Denmark represent the next evolution of our “Sky Class” cultivation philosophy and construction of these projects is proceeding well. Aurora Sun is nearing completion with the majority of capital investment now behind us, while at Aurora Nordic the primary outdoor construction, including the enclosure of the facility, nears completion. Our design philosophy allows for flexibility in licensing and commissioning in-line with the long-term growth in global demand for medical cannabis.”

William SumnerWilliam SumnerSeptember 11, 2019


It’s time for your Daily Hit of cannabis financial news for September 11, 2019.

Medicine Man Technologies

Medicine Man Technologies, Inc. (OTCQX: MDCL) has entered into a binding term sheet to acquire the cannabis operator Strawberry Fields for $31 million. The acquisition is comprised of $14 million in cash and $17 million in common stock, priced at $2.98 per share. “The integration of Strawberry Fields into our family of Colorado pioneers will be impactful,” said Andy Williams, Co-Founder and CEO of Medicine Man Technologies. “This transaction will provide our Company with low-cost cultivation assets located in Pueblo, a growing manufacturing facility, and branded products. In addition we will be acquiring four retail locations in Western and Southern Colorado, including a high yielding store that is a leader in that part of the state. Adding Strawberry Fields to our portfolio will strengthen our strategy to become the leading integrated cannabis operator of Colorado.”


After the market close yesterday, Tilray Inc. (NASDAQ: TLRY) announced in an 8k-filing that it has selected Cowen and Company to sell up to $400 million in stock once an S-3 registration statement is effective, with any sales to be an “at-the-market offering.”

Vapen MJ

Vapen MJ Ventures (OTCQX:VAPNF) announced the appointment of Arizona Attorney Scott A. Hill to the company’s advisory board. Hill is a patent attorney and former stock broker licensed to practice law in the state of Arizona and in the United States District Court for the District of Arizona. “Scott was instrumental in successfully working with the USPTO for Vapen MJ’s utility patent for our Cannabinoid Inhaler without a heating element. Scott crafted the claim in the filing, which makes the recently granted patent as broad as possible,” commented Thai Nguyen, Founder and CEO of Vapen MJ.

Aurora Cannabis

Aurora Cannabis (NYSE: ACB) announced the release of its financial results for the fourth quarter, ending on June 30, 2019. Net revenue for the quarter rose by 61% to $94.6 million. The cost-per gram sold declined t0 $1.14. The gross margin was 58% and adjusted EBITDA was a loss of $11.7 million. “In 2019 Aurora took its place as the global leader in cannabis production, research, innovation, and international market development. We are executing on all our strategic priorities,” said Terry Booth, Aurora CEO. “Our best in class cultivation methods allow us to grow consistent, high-quality cannabis at scale.”

StaffStaffSeptember 4, 2019


Editors note: Guest post by Mark Putrino, CMT Sep 3, 2019, 10:05 am EDT

Are ACB’s sales being affected by the robust black market? I think the answer is yes.

Aurora Cannabis (NYSE:ACB) has a well-defined path to profitability. Its near-term goal is to drive down costs by leveraging its massive scale to improve margins. Its medium-term goal is to leverage R&D to work on higher-margin products and to harvest the Canadian cash flow that is generated from its near-term goals. Long-term, the goal is to use extensive R&D to develop and brand higher-margin products.

Wall Street likes ACB stock. Out of the 17 firms that follow it, 10 of them have it ranked either as a buy or overweight. The average target price is more than two times higher than where it is currently trading.

In addition, unlike many of the other large industrial growers, this company reported an actual profit last year, something that is rarely seen in this industry. In fiscal 2019, the company earned 15 cents a share.

Despite all of these positives, the price of ACB stock continues to decline. Why is this happening? Being a veteran of the markets I know that it is impossible to give an exact and definitive reason.

But I believe that a challenge facing Aurora Cannabis and other cannabis growing companies which isn’t discussed too often is the negative effect that the supply from the black market has on their sales.

The Black-Green Market

If you follow the cannabis markets you are probably aware that two recent stories involve litigation issues other than legalization. Canntrust (NYSE:CTST) is alleged to have operated unlicensed, and therefore untaxed and illegal, grow rooms. These were literally hidden behind fake walls.

In addition, the FBI just announced that it will be investigating the industry. Sources tell me that their main focus will be on the alleged kickbacks that are required in some places in order to obtain a growing license. I believe that their investigation will expose and shed light on the enormous size of the black market of cannabis.

Is the cannabis black market efficient and profitable? You bet it is. As someone who has many connections in law enforcement and the cannabis industry, I can tell you that the black market for recreational cannabis is enormous. And this market is virtually, if not literally, impossible to control.

Consider a cannabis farm of 2,000 acres. You don’t need a vivid imagination to understand how easy it will be for employees and others to walk off with product or to send it out the proverbial back door. In fact, I have talked to recreational marijuana enthusiasts in Canada that enjoy it daily. Yet none have purchased it from a licensed retailer since it became legal almost a year ago.  Why go to the store when someone in the park across the street has the same thing for half the price?

As long as these dynamics exist, industrial growers like Aurora Cannabis will have to accept and face this challenge as part of their growth strategies.

A Look at Aurora Cannabis Stock

ACB stock has been trending lower since it failed at resistance at the $7 level in early August. If it continues to trend lower, there may be support around the $5 level. This is where support was in December and January and it is also important psychologically.

At the time of this writing, Mark Putrino did not hold a position in any of the aforementioned securities.


Debra BorchardtDebra BorchardtSeptember 4, 2019


Aurora Cannabis Inc.  (NYSE | TSX: ACB) sold off its final 28,833,334 shares of The Green Organic Dutchman Holdings Ltd (CSE: TGOD) (OTC: TGODF) at a price of $3.00 per share for gross proceeds of roughly $86.5 million. The stock was lately trading at C$3.51 on the CSE and $2.63 on the OTC. The share represent 10.5% of the issued and outstanding shares of TGOD.

“Aurora has a broad portfolio of strategic investments that allow us to participate in opportunities throughout the cannabis sector, while providing the company with non-dilutive access to capital,” said Terry Booth, CEO of Aurora. “We evaluate our investment portfolio on a regular basis to make sure it continues to align with our investment strategy and corporate priorities. When we acquired Whistler Medical Marijuana Corporation – an iconic and premium organic cannabis producer – our interest in TGOD became less important to our core strategy. Our return on our TGOD investment is significant and will add non-dilutive capital and further enhance our strategy to remain a dominant force in the global cannabis industry.”

The investment turned out to be a winner for Aurora. The company said that the sale represented an approximate 50% internal rate of return for the company. Aurora said it no longer holds any shares of TGOD, but it does continue to hold warrants to purchase 16,666,667 shares of TGOD.

TGOD stock got a lift on Tuesday after announcing it got approval from Health Canada to expand operations into its new hybrid greenhouse located in Hamilton, Ontario. The new facility is the third phase of TGOD’s Hamilton site, measuring 166,000 square feet with an annual production capacity of 17,500 kgs of premium organic cannabis.

Mo Money

Selling the TGOD shares was a quick way to bring money to the company’s coffers. In June, Stifel initiated coverage of Aurora with a Hold rating. The analyst W. Andrew Carter wrote, “Aurora Cannabis’ near-term growth strategy hinges heavily on its ability to return to the capital markets. The company has filed a base shelf prospectus of $750 million (roughly C$1 billion) and in conjunction with its 3Q19 earnings release, announced a supplement that included a $400 million of “at-the-market” distributions over a period of up to 25 months.”

At that time the stock was trading at C$10.65 and the analyst had a target price of C$10.00. The stock was lately trading at C$7.57.

The analyst went on to add, ” We question if Aurora has fully embraced the level of investment necessary to sustain a leading position in the Canadian market, and we believe the company could be challenged without the expertise of a consumer partner with a vested interest in the success of Aurora.”

William SumnerWilliam SumnerAugust 15, 2019


It’s time for your Daily Hit of cannabis financial news for August 15, 2019.

On the Site


Yesterday, Trulieve Cannabis Corp. (OTCMKTS: TCNNF) (CNSX: TRUL) announced the release of its second quarter financial results. Year-over-year, Trulieve’s increased 149% from $23.3 million to $57.9 million. Keeping pace with revenue, operating expenses also rose from $6 million to 14.8 million, representing a 146% increase. Gross profit was $37.6 million, and the gross profit margin was 65%. Adjusted EBITDA was $31.6 million.

Harvest Health & Recreation

Harvest Health & Recreation, Inc. (CSE: HARV) (OTCQX: HRVSF) has reported its financial results for the second quarter, ending on June 30, 2019. Revenue rose from $19.2 million in the previous quarter to $26.6 million, representing an increase of 39%. If one were to include Harvest Health’s completed and pending acquisitions, quarterly revenue would be $78 million.

Money Moves From Aurora Cannabis, Green Growth Brands

Aurora Cannabis Inc.  (NYSE | TSX: ACB) said that it has secured commitments from an expanded syndicate of lenders led by the Bank of Montreal to amend and upsize its existing C$200 million secured credit facility.

Green Growth Brands Inc. (CSE:GGB) (OTCQB:GGBXF) said that it has entered into backstop commitment letters with each of All Js Greenspace LLC, Park Lane Capital Limited, and Chiron Ventures Inc. in which they have committed to subscribe for and purchase up to C$102,796,241 in the aggregate or roughly $77 million of convertible debentures to support the Company’s operations and capital needs.

Canopy Growth

Canopy Growth Corporation  (TSX: WEED) (NYSE: CGC) stock dropped over 10% after the company announced its financial results for the first quarter ending June 30, 2019. The worst of the news in the release was that the company’s fiscal first-quarter net losses of C$1.28 billion, or C$3.70 a share, dwarfed last year’s losses of C$91 million, or 40 cents a share. The loss was attributed to a non-cash charge of $1.2 billion in Canopy’s extinguishing warrants related to the Constellation Brands Inc. (NYSE: STZ) investment.

In Other News

Vireo Health

Vireo Health International, Inc. (CNSX: VREO) (OTCQX: VREOF) announced that its affiliate, Ohio Medical Solutions (OMS), has been granted a Certificate of Operation by the Ohio Department of Commerce. OMS, which was previously granted a provisional processing license, will begin operations immediately. The license will allow OMS to purchase plant material from cultivators and manufacture Vireo-branded medical cannabis products.  “We are delighted that Ohio Medical Solutions will begin manufacturing Vireo products for the benefit of Ohio patients,” said Vireo CEO, Kyle Kingsley, M.D. “The City of Akron has been great to us and as our business grows, we look forward to continuing to create new jobs and make a positive impact on the local economy.”

Front Range Biosciences

Front Range Biosciences (FRB) announced that it has entered a collaborative licensing agreement with Steep Hill, and that it will acquire Steep Hill’s Genomics Research & Development team. The agreement will help accelerate FRB’s marker-assisted breeding program and develop new traits and varieties of hemp and cannabis. “The Steep Hill R&D team is among the top three cannabis genomics groups in the world, and we are very excited to welcome them to FRB,” said Dr. Jonathan Vaught, CEO and Co-Founder of FRB. “This acquisition is a major value inflection point for FRB…”

Medical Marijuana Inc.

Medical Marijuana Inc. has filed its financial results for the second quarter. Revenue rose 30.8% to $20.7 million. Gross profit was $15.4 million and adjusted EBITDA was $1.5 million. General and administrative expenses decreased from 21% of sales in Q2 2018 to 16% of sales revenue. “We are excited to continue our tremendous sequential success with the second quarter of 2019 proving to be the largest sales revenue quarter in the history of our Company,” said Dr. Stuart Titus, CEO of Medical Marijuana, Inc. “As the world continues to become more receptive to learning about the benefits of hemp-derived CBD, we are enthusiastic about being at the forefront of the global cannabis industry which, according to Arcview Market Research, could be worth $57 billion by 2027.”

Debra BorchardtDebra BorchardtAugust 15, 2019


Aurora Cannabis

Aurora Cannabis Inc.  (NYSE | TSX: ACB) said that it has secured commitments from an expanded syndicate of lenders led by the Bank of Montreal to amend and upsize its existing C$200 million secured credit facility.

The company said that its amended secured credit facility will consist of an additional C$160 million allocated between both term loans and a revolving credit facility, both of which will mature in August 2021. The credit facility will have a first ranking general security interest in the assets of Aurora. The loans can be repaid without penalty at Aurora’s discretion.

“The upsizing of our credit facility to approximately C$360 million and the broadening of the lending syndicate to include additional Schedule 1 Canadian Banks is further recognition that our best-in-class production facilities lead the industry,” said Glen Ibbott, CFO of Aurora.  “Access to this non-dilutive capital is a core funding source the Company intends to utilize as it further executes on its strategic growth initiatives. In addition to cash being generated from operations, the Company also has access to other unsecured debt alternatives, a number of equity investments, and has access to a C$514 million (US$400 million) At-The-Market equity program (“ATM”).”

Green Growth Brands

Green Growth Brands Inc. (CSE:GGB) (OTCQB:GGBXF) said that it has entered into backstop commitment letters with each of All Js Greenspace LLC, Park Lane Capital Limited, and Chiron Ventures Inc. in which they have committed to subscribe for and purchase up to C$102,796,241 in the aggregate or roughly $77 million of convertible debentures to support the Company’s operations and capital needs.

In addition,  Green Growth said that it is having discussions and has signed a letter of intent with United Capital Partners LLC to obtain additional debt financing of up to $50 million. If secured, it is anticipated that the Proposed Debt Financing would be used by Green Growth to fund, in part, the company’s presently identified capital and operating expenditures related to the opening of new dispensaries, new mall-based CBD kiosk shops and the acquisition or build-out of a cultivation facility in Florida.

Debra BorchardtDebra BorchardtAugust 6, 2019


Aurora Cannabis Inc.  (NYSE | TSX: ACB) gave an update on selected financial metrics for the fourth quarter of the company’s fiscal 2019 period ending June 30, 2019. While the information is selectively limited, Aurora said it feels it is being transparent by releasing the data and that the full results will be published prior to September 15, 2019. The company did not report any expense figures or any data relating to net profits or losses. The stock seemed to get a boost as the price was lifted by 5% in premarket trading.

Fourth Quarter

Based on a preliminary and unaudited review, Aurora said that it expects net revenues for the quarter to range between $100 million and $107 million (net of excise taxes) versus last year’s $19.1 million for the same time period. Sequentially, it is an increase over the $65.1 million reported for the quarter ending in March.  The company said that the fiscal Q4 2019 net cannabis revenue is expected to be between $90 million and $95 million, with growth anticipated across all key business segments including medical, both Canadian and international, and consumer markets.

Full Year

Aurora also said that it is forecasting that the total net revenues for the fiscal year ending June 30, 2019 should be in the range of $249 million – $256 million. The company also said that it expects to report that products available for sale for the fourth quarter will be at the upper end of the range between 25,000 kg and 30,000 kg, ahead of previous guidance of 25,000 kgs.

“Our Q4 2019 guidance highlights Aurora’s continued leadership,” said Terry Booth, CEO of Aurora. “We set out to be best-in-class cultivators, and through carefully evaluated acquisitions, that vision continues to drive exceptional results today. We are the leader in cultivation capacity, production available for sale and revenues for cannabis in the Canadian medical and consumer markets. We continue to lead the build-out of European and other international medical cannabis markets. Our success to date comes from a focus on quality, regulatory compliance, appropriate Board of Directors oversight, and delivering a profitable, low risk and sustainable business for our shareholders.”

William SumnerWilliam SumnerJuly 23, 2019


Amplify Investments is getting into the cannabis industry. Today, Amplify ETF’s announced the launch of Amplify Seymour Cannabis ETF (NYSE Arca: CNBS), an actively managed ETF covering the cannabis industry. Tim Seymour, CIO of Seymour Asset Management and CNBC Fast Money co-host, will act as the fund’s portfolio manager.

As one of the world’s most premier financial journalists, Seymour recently served as the headline speaker for the Green Market Summit in Chicago, Illinois. You can watch his fireside chat with Peter Miller, CEO of Slang Worldwide Inc. (SLGWF), about the explosive growth of the cannabis industry here.

“The global legal cannabis industry is still very much in its infancy and presents an attractive growth opportunity for investors looking to capitalize on this emerging frontier,” Seymour said. “Amplify has a track record of offering investors access to disruptive areas of the market via the ETF structure, and the cannabis industry certainly fits this mold.”

As portfolio manager, Seymour will base his decisions off of publicly available data, regulatory filings, third party research, and his evaluations of companies’ financial fundamentals.

The CNBS portfolio will include cannabis companies that are federally legal in the countries in which they operate. Specifically, the portfolio will cover companies that fall into one of three categories: cannabis/hemp plant, support cultivation and retail, and ancillary companies that provide goods and services to the cannabis industry.

Another qualification is that at least 80% of the companies in the ETF must receive 50% or more of their revenue from the hemp or cannabis industry. The fund portfolio currently covers 25 of the cannabis industry’s leading companies; such as Aurora Cannabis (NYSE: ACB), Canopy Growth (NYSE: CGC), Hexo Corp. (NYSE: HEXO), Tilray (NASDAQ: TLRY), and WeedMD (OTCMKTS: WDDMF)

“Cannabis and hemp are seeing a new wave of potential use cases across multiple industries, and investors are eager to gain access to this emerging sector,” said Christian Magoon, founder and CEO of Amplify ETFs. “Tim is a recognized voice and active investor in the cannabis space, and we’re excited to harness his investment expertise and specialized insights to navigate and capture the expanding opportunity in the rapidly evolving industry.”

About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


Recent Tweets

@GreenMarketRpt – 36 mins

‘Psychedelic Renaissance’ Momentum Underscored by Sold Out Conference on ⁦@cheddar⁩ thanks ⁦@chlobo_ilo⁩ for coming…

@GreenMarketRpt – 3 hours

“Hot Plants” Prove Problematic for Entrepreneurs

@GreenMarketRpt – 2 days

$SNNVF Troubles Continue For , Company Announces Ceasing Operations Of Full-Scale Distributors, LLC

Back to Top

You have Successfully Subscribed!